Scalp application of antioxidants improves scalp condition and reduces hair shedding in a 24-week randomized, double-blind, placebo-controlled clinical trial

被引:15
|
作者
Davis, Michael G. [1 ]
Piliang, Melissa P. [2 ,3 ]
Bergfeld, Wilma F. [2 ,3 ]
Caterino, Tamara L. [1 ]
Fisher, Brian K. [1 ]
Sacha, Jarek P. [1 ]
Carr, Gregory J. [1 ]
Moulton, Laura T. [1 ]
Whittenbarger, Deborah J. [1 ]
Schwartz, James R. [1 ]
机构
[1] Procter & Gamble Co, Mason, OH 45040 USA
[2] Cleveland Clin, Dept Dermatol, Cleveland, OH 44106 USA
[3] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA
关键词
antioxidant; hair growth; hair loss; hair shedding; hair treatment; scalp; skin barrier; OXIDATIVE STRESS; ANDROGENETIC ALOPECIA; SEBORRHEIC DERMATITIS; PROTEIN OXIDATION; PYRITHIONE ZINC; DAMAGE; DISORDERS; MINOXIDIL; RADICALS; DANDRUFF;
D O I
10.1111/ics.12734
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Objective Increasing hair fullness is a global unmet need for many men and women. An approach to the problem is to decrease hair fall or shedding by reducing scalp stratum corneum oxidation and barrier damage to increase hair retention. This study evaluated a combination of functional antioxidants and barrier-enhancing cosmetic ingredients to improve scalp condition thereby enabling stronger hair anchorage and longer retention. Methods Male and female subjects with normal scalp condition and self-perceived hair thinning participated in a 24-week, double-blind, placebo-controlled, randomized clinical study assessing either a regimen of treatment shampoo and leave-on treatment containing functional antioxidant and barrier-enhancing agents or an identical placebo chassis shampoo control. The functional ingredients were piroctone olamine, zinc pyrithione, zinc carbonate, niacinamide, panthenol and caffeine. At baseline and after 8, 16 and 24 weeks of product use, several measurements were taken: hair shedding, total hair count (by phototrichogram), hair samples, TEWL and evaluation of biomarkers of scalp and hair conditions. Subjects also completed self-assessment questionnaires. Results Statistically significant effects for functional ingredient-containing treatment regimen versus a placebo control shampoo formulation were observed for reduced hair shedding, increased total hair count, reduced TEWL and improvement in scalp biomarker values. Subjects also noticed these improvements assessed via self-assessment questionnaires. Conclusions These results establish that the use of functional antioxidant and barrier-enhancing agents to further improve scalp condition can enable a reduction in hair shedding and thus an increase in perceived hair fullness. The underlying improvements in scalp condition suggest the hair benefits were achieved as a result of improved scalp skin barrier and scalp condition leading to a viable preventative approach for hair thinning.
引用
收藏
页码:S14 / S25
页数:12
相关论文
共 50 条
  • [21] Treatment of Major Depressive Disorder Using Botulinum Toxin A: A 24-Week Randomized, Double-Blind, Placebo-Controlled Study
    Magid, Michelle
    Reichenberg, Jason S.
    Poth, Poppy E.
    Robertson, Henry T.
    LaViolette, Amanda K.
    Kruger, Tillmann H. C.
    Wollmer, M. Axel
    JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (08) : 837 - +
  • [22] Weight Maintenance with Litramine (IQP-G-002AS): A 24-Week Double-Blind, Randomized, Placebo-Controlled Study
    Grube, Barbara
    Chong, Pee-Win
    Alt, Felix
    Uebelhack, Ralf
    JOURNAL OF OBESITY, 2015, 2015
  • [23] Resveratrol reduces albuminuria in diabetic nephropathy: A randomized double-blind placebo-controlled clinical trial
    Sattarinezhad, A.
    Roozbeh, J.
    Yeganeh, B. Shirazi
    Omrani, G. R.
    Shams, M.
    DIABETES & METABOLISM, 2019, 45 (01) : 53 - 59
  • [24] Escitalopram Treatment for Depressive Disorder Following Acute Coronary Syndrome: A 24-Week Double-Blind, Placebo-Controlled Trial
    Kim, Jae-Min
    Bae, Kyung-Yeol
    Stewart, Robert
    Jung, Bo-Ok
    Kang, Hee-Ju
    Kim, Sung-Wan
    Shin, Il-Seon
    Hong, Young Joon
    Kim, Ju Han
    Shin, Hee-Young
    Kang, Gaeun
    Ahn, Youngkeun
    Kim, Jong-Keun
    Jeong, Myung Ho
    Yoon, Jin-Sang
    JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (01) : 62 - U138
  • [25] DONEPEZIL SIGNIFICANTLY IMPROVES ABILITIES IN DAILY LIVES OF FEMALE DOWN SYNDROME PATIENTS WITH SEVERE COGNITIVE IMPAIRMENT: A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Kondoh, Tatsuro
    Kanno, Atsushi
    Itoh, Hiroshi
    Nakashima, Mikiro
    Honda, Ryoko
    Kojima, Michio
    Noguchi, Mitsuru
    Nakane, Hideyuki
    Nozaki, Hidetsugu
    Sasaki, Hitoshi
    Nagai, Toshiro
    Kosaki, Rika
    Kakee, Naoko
    Okuyama, Torayuki
    Fukuda, Masafumi
    Ikeda, Masayuki
    Shibata, Yoshisada
    Moriuchi, Hiroyuki
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 2011, 41 (01): : 71 - 89
  • [26] THIAZIDE REDUCES BONE LOSS - A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    WASNICH, RD
    DAVIS, JW
    HE, YF
    PETROVICH, H
    ROSS, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 1993, 8 : S123 - S123
  • [27] Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
    Haering, Hans-Ulrich
    Merker, Ludwig
    Seewaldt-Becker, Elke
    Weimer, Marc
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES CARE, 2013, 36 (11) : 3396 - 3404
  • [28] Muraglitazar, a dual (α/γ) PPAR activator:: A randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
    Buse, JB
    Rubin, CJ
    Frederich, R
    Viraswami-Appanna, K
    Lin, KC
    Montoro, R
    Shockey, G
    Davidson, JA
    CLINICAL THERAPEUTICS, 2005, 27 (08) : 1181 - 1195
  • [29] Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis
    Sanyal, Arun
    Ling, Lei
    Neff, Guy
    Guy, Cynthia
    Bashir, Mustafa
    Paredes, Angelo
    Frias, Juan
    Younes, Ziad H.
    Trotter, James F.
    Gunn, Nadege T.
    Moussa, Sam
    Kohli, Anita
    Nelson, Kristen
    Gottwald, Mildred
    Chang, William
    Yan, Andrew
    DePaoli, Alex
    Lieu, Hsiao
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2021, 75 : S616 - S617
  • [30] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270